Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Calysta’s FeedKind® Protein Successful as a Complete Fishmeal Replacement in Shrimp Feed

Calysta,Inc.
Posted on: 15 Aug 17

Calysta, Inc. today announced that shrimp fed a diet including FeedKind® protein had equivalent or higher survival and growth when compared to shrimp fed a standard fishmeal-based diet. Calysta’s FeedKind protein is a family of natural, sustainable and traceable feed ingredients for livestock, fish and pets. Trial results were announced at AquaNor, the world’s largest aquaculture technology exhibition.

The trial is Calysta’s first study in warm water aquaculture, and represents an entry into the six million metric ton global shrimp feed market. The trial was performed at Auburn University in conjunction with Texas A&M University.

In the trial, post-larvae Pacific white shrimp (Litopenaeus vannamei)were fed a commercially representative control diet containing fishmeal as a primary source of protein. Test diets were prepared where FeedKind protein replaced up to 100% of the fishmeal in the diet on a one-for-one basis. The animals were fed either the control or a test diet for eight weeks in a controlled environment. At the end of the study, shrimp survival was significantly improved in all FeedKind diets (93-97%) compared to the control diet (84%). In addition, the total shrimp weight in all FeedKind diet groups was shown to be equivalent to or improved versus the control fishmeal diet.

“This is a significant expansion of the global market opportunity for FeedKind,” said Josh Silverman, Ph.D., Calysta Founder and Chief Product and Innovation Officer. “FeedKind is being developed to meet the world’s growing demand for food and feed, and this trial demonstrates FeedKind’s potential to improve the diets in some of the world’s most challenging aquaculture species. These results show that FeedKind protein can significantly improve current aquaculture feeds, producing comparable or better results while reducing the overall environmental footprint and improving traceability and quality control in the supply chain.”

“Shrimp remain one of the most valuable seafood commodities within aquaculture, with global trade of more than $20 billion per year,” said Ronnie Tan, a member of the Calysta Advisory Board and Vice President of Blue Archipelago, the largest shrimp enterprise in Malaysia. “Innovative products such as FeedKind will be important new market entries as demand grows in emerging countries for new sources of protein.”

FeedKind is a safe, sustainable, non-animal source of protein approved for sale in multiple countries, and has been shown to use 77-98% less water and >98% less land than alternative ingredients such as soy or wheat proteins. Samples are currently available for global customers and partners in markets including the European Union, the United States, China, Japan, Southeast Asia, and Australia.

About Calysta

Calysta, Inc., Menlo Park, CA, is an innovator in sustainable products to improve worldwide food security. Calysta develops and commercializes FeedKind® protein, an alternative feed ingredient for fish, livestock and pet nutritional products.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170815005128/en/

Business Wire
www.businesswire.com

Last updated on: 15/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.